

“If the hybrid systems will really work, then they are going to be more widely distributed, and should lead the path. BUT! if they are only half-breeds with half performance, then don't bother till the PET/CT combo is proven to really be useful.”

“The location of the abnormality, the size of the abnormality, the sharpness of the borders of the abnormality, the uniformity or nonuniformity of the abnormality, and the number of abnormalities are qualities that could help to define the pathology and are usually not considered in the above analyses. I do not believe that we have a good way of determining the efficacy of either the individual procedures or ‘fused’ procedures.”

I hope this information is useful to manufacturers as well as to nuclear medicine and other physicians. Please let me know whether you believe these questionnaires are helpful (if they are not overdone): e-mail (hwagner@jhsp.edu) or fax (410-955-6222).

—Henry N. Wagner, Jr., MD

NCI Announces Initiatives

According to Barbara Croft, PhD, Diagnostic Imaging Program, National Cancer Institute, the NCI has announced the following initiatives:

Diagnostic Imaging and Guided Therapy in Prostate Cancer (Phased Innovation Award) (RFA CA-99-015) National Cancer Institute and National Institute on Aging.

Letter of Intent Receipt Date: October 20, 1999;
Application Receipt Date: November 17, 1999.

The Diagnostic Imaging Program of the NCI and the NIA invite applications on the development, risk assessment, and application of improved imaging methods for the localization, biopsy and image-guided biopsy or therapy of prostate cancer. Relevant investigations could include technology development, in vitro laboratory work, preclinical animal studies or early feasibility testing in humans depending on the maturity of the methods proposed, or evaluation of the effects

of age-associated changes and comorbid conditions as they affect imaging diagnosis and treatment techniques.

For more information see the following web site: <http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-99-015.html>

Diagnostic Imaging and Guided Therapy in Prostate Cancer: SBIR/STTR Initiative (PAR-99-149) National Cancer Institute and National Institute on Aging.

Letter of Intent Receipt Date: October 20, 1999;
Application Receipt Date: November 17, 1999.

This is a companion announcement to the above for the small business community.

For more information, see the following web site: <http://grants.nih.gov/grants/guide/pa-files/PAR-99-149.html>